FIELD: medicine.
SUBSTANCE: invention refers to medicine and represents a method for prediction of response of oncological patient with non-Hodgkin's lymphoma to anticancer therapy, including bortezomib and rituximab, characterized by that the method involves determination of level or amount of first prognostic factor and determination of presence or amount of second prognostic factor, wherein low level of CD68 or polymorphism of PSMB1 (P11A) correlates with, at least, one positive result. Invention also relates to a diagnostic kit for detecting oncological patients with non-Hodgkin's lymphoma, which are candidates for treating cancer with bortezomib and rituximab, as well as method of treating cancer in oncological patients with non-Hodgkin's lymphoma.
EFFECT: invention implementation enables predicting positive response of oncology patient to combination therapy of bortezomib and rituximab.
7 cl, 5 ex, 25 tbl, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CANCER TREATMENT | 2015 |
|
RU2651469C1 |
| METHOD OF PREDICTING EFFICIENCY OF TREATMENT OF PATIENTS WITH HIGH GRADE NON-HODGKIN LYMPHOMA | 2013 |
|
RU2533816C2 |
| BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS | 2014 |
|
RU2658601C2 |
| BIOMARKERS FOR COMBINED THERAPY INCLUDING LENVATINIB AND EVEROLIMUS | 2016 |
|
RU2745060C2 |
| PREDICTIVE BIOMARKER FOR CANCER THERAPY | 2014 |
|
RU2672358C2 |
| METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST | 2019 |
|
RU2788524C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| METHOD FOR PREDICTION OF EFFECTIVENESS OF CONSERVATIVE TREATMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 2023 |
|
RU2817324C1 |
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| CHROMOGRANIN A AS MARKER OF BLADDER CANCER | 2017 |
|
RU2785737C2 |
